Early maternal depressive symptoms and child growth trajectories: a longitudinal analysis of a nationally representative US birth cohort

Surkan, Pamela J.; Ettinger, Anna K.; Hock, Rebecca S.; Ahmed, Saifuddin; Strobino, Donna M.; Minkovitz, Cynthia S.

doi:10.1186/1471-2431-14-185

Cited by 47 publications

(49 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Grote et al, 14 in a study conducted in European countries, also found no differences concerning overweight or obesity comparing children exposed to maternal depression symptoms in the postpartum period with those not exposed. The same results were observed by Surkan et al, 2 in 2001, in a study carried out in the United States. In the unadjusted model, there was a statistically significant association, but after adjustment, the association was no longer sustained.…”

Section: Variables Psupporting

confidence: 88%

“…12 Studies suggest that this association is linked to a lack of maternal care and related to a deficient mother-child bond, low family support, precarious economic situation and local customs. 2,5,6,12,25 In rural Bangladesh, located in South Asia, Black et al, 26 detected, in 2009, the same results as in Pakistan. This study demonstrated that children of mothers with depression symptoms were almost twice more likely to be malnourished (OR= 2.17 95%CI= 1.24 -3.81, p=0.007).…”

Section: Discussionmentioning

confidence: 85%

“…The literature suggests that postpartum maternal depression symptoms influence motherchild interaction and, consequently, maternal care, increasing the risk of child malnutrition. 2,5,6,12,25 However, Harpham et al, 11 have shown that even in countries with high rates of malnutrition, like Ethiopia (38%) and Vietnam (16%), the results do not corroborate with those of previous studies. In our study, children of mothers with depression symptoms were not more likely to be malnourished either (OR: 1.09, 95% CI: 0.62 -1.89, p=0.768).…”

Section: Variables Pmentioning

confidence: 86%

“…1,2 The prevalence of overweight and obesity has increased worldwide. 3 This trend is also being observed among children.…”

Section: Introductionmentioning

confidence: 99%

“…5 The role of maternal depression in the development of the child has been questioned in the literature. 2,6,7 It is known that gestation and the puerperium are periods of a woman's life involving innumerable physical, hormonal and psychic changes, which may impact directly in her mental health. Studies show that about one-fifth of women has depressive symptoms in the gestational period and that undiagnosed and untreated psychiatric disorders in pregnant women can lead to serious maternal-fetal consequences.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Association between maternal depressive symptoms with child malnutrition or child excess weight

Lima

Maciel

Alencar

et al. 2017

Rev. Bras. Saude Mater. Infant.

View full text Add to dashboard Cite

Objectives: to verify associations between maternal depressive symptoms with child malnutrition or child excess weight.Methods: prospective study with data from the BRISA prenatal cohort in São Luís, Brazil, obtained from the 22nd to the 25th week of gestation (in 2009 and 2010) and, later, when children were aged 12 to 32 months (in 2010 and 2012) . Maternal depressive symptoms were identified using the Center for Epidemiologic Studies Depression Scale (CES-D) and the Edinburgh Postnatal Depression Scale (EPDS

show abstract

Section: Variables Psupporting

confidence: 88%

Section: Discussionmentioning

confidence: 85%

Section: Variables Pmentioning

confidence: 86%

“…1,2 The prevalence of overweight and obesity has increased worldwide. 3 This trend is also being observed among children.…”

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Association between maternal depressive symptoms with child malnutrition or child excess weight

Lima

Maciel

Alencar

et al. 2017

Rev. Bras. Saude Mater. Infant.

View full text Add to dashboard Cite

show abstract

Effect of Zuranolone vs Placebo in Postpartum Depression

et al. 2021

View full text Add to dashboard Cite

IMPORTANCE Postpartum depression (PPD) is one of the most common medical complications during and after pregnancy, negatively affecting both mother and child.OBJECTIVE To demonstrate the efficacy and safety of zuranolone, a neuroactive steroid γ-aminobutyric acid receptor-positive allosteric modulator, in PPD. DESIGN, SETTING, AND PARTICIPANTSThis phase 3, double-blind, randomized, outpatient, placebo-controlled clinical trial was conducted between January 2017 and December 2018 in 27 enrolling US sites. Participant were women aged 18 to 45 years, 6 months or fewer post partum, with PPD (major depressive episode beginning third trimester or Յ4 weeks postdelivery), and baseline 17-item Hamilton Rating Scale for Depression (HAMD-17) score of 26 or higher. Analysis was intention to treat and began December 2018 and ended March 2019.INTERVENTIONS Randomization 1:1 to placebo:zuranolone, 30 mg, administered orally each evening for 2 weeks. MAIN OUTCOMES AND MEASURESPrimary end point was change from baseline in HAMD-17 score for zuranolone vs placebo at day 15. Secondary end points included changes from baseline in HAMD-17 total score at other time points, HAMD-17 response (Ն50% score reduction) and remission (score Յ7) rates, Montgomery-Åsberg Depression Rating Scale score, and Hamilton Rating Scale for Anxiety score. Safety was assessed by adverse events and clinical assessments. RESULTSOf 153 randomized patients, the efficacy set comprised 150 patients (mean [SD] age, 28.3 [5.4] years), and 148 (98.7%) completed treatment. A total of 76 patients were randomized to placebo, and 77 were randomized to zuranolone, 30 mg. Zuranolone demonstrated significant day 15 HAMD-17 score improvements from baseline vs placebo (−17.8 vs −13.6; difference, −4.2; 95% CI, −6.9 to −1.5; P = .003). Sustained differences in HAMD-17 scores favoring zuranolone were observed from day 3 (difference, −2.7; 95% CI, −5.1 to −0.3; P = .03) through day 45 (difference, −4.1; 95% CI, −6.7 to −1.4; P = .003). Sustained differences at day 15 favoring zuranolone were observed in HAMD-17 response (odds ratio, 2.63; 95% CI, 1.34-5.16; P = .005), HAMD-17 score remission (odds ratio, 2.53; 95% CI, 1.24-5.17; P = .01), change from baseline for Montgomery-Åsberg Depression Rating Scale score (difference, −4.6; 95% CI, −8.3 to −0.8; P = .02), and Hamilton Rating Scale for Anxiety score (difference, −3.9; 95% CI, −6.7 to −1.1; P = .006). One patient per group experienced a serious adverse event (confusional state in the zuranolone group and pancreatitis in the placebo group). One patient in the zuranolone group discontinued because of an adverse event vs none for placebo. CONCLUSIONS AND RELEVANCEIn this randomized clinical trial, zuranolone improved the core symptoms of depression as measured by HAMD-17 scores in women with PPD and was generally well tolerated, supporting further development of zuranolone in the treatment of PPD.

show abstract

Maternal major depression disorder misclassification errors: Remedies for valid individual‐ and population‐level inference

Owora

2022

Brain and Behavior

View full text Add to dashboard Cite

Individual and population level inference about risk and burden of MDD, particularly maternal MDD, is often made using case‐finding tools that are imperfect and prone to misclassification error (i.e. false positives and negatives). These errors or biases are rarely accounted for and lead to inappropriate clinical decisions, inefficient allocation of scarce resources, and poor planning of maternal MDD prevention and treatment interventions. The argument that the use of existing maternal MDD case‐finding instruments results in misclassification errors is not new; in fact, it has been argued for decades, but by and large its implications and particularly how to correct for these errors for valid inference is unexplored. Correction of the estimates of maternal MDD prevalence, case‐finding tool sensitivity and specificity is possible and should be done to inform valid individual and population‐level inferences.

show abstract

Early maternal depressive symptoms and child growth trajectories: a longitudinal analysis of a nationally representative US birth cohort

Cited by 47 publications

References 26 publications

Association between maternal depressive symptoms with child malnutrition or child excess weight

Association between maternal depressive symptoms with child malnutrition or child excess weight

Effect of Zuranolone vs Placebo in Postpartum Depression

Maternal major depression disorder misclassification errors: Remedies for valid individual‐ and population‐level inference

Contact Info

Product

Resources

About